u/the_jetset

The post cites a forward P/E of ~14 (compressed), FCF/share of $4.24, 3% dividend yield, ~0.75% buyback potential, 11.5% organic growth, and multiple insider purchases between $91–$108. This data suggests the market underestimates ABT’s intrinsic value. A reversion to a P/E of 19–20 would yield 35–43% price appreciation, plus dividends and buybacks, making the risk/reward asymmetric. A long position in ABT offers a margin of safety with a downside floor near the current PE (~13–14) and upside from multiple expansion, organic growth, and shareholder returns. Higher debt from the Exact Sciences acquisition could pressure margins or delay deleveraging; a recession or regulatory headwind could compress organic growth; the compressed PE may persist if sentiment remains negative.